Ertug Toroslu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ertug Toroslu has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Aslı Tetik Vardarlı
Department of Medical Biology, Faculty of Medicine Ege University Izmir Türkiye
1 shared publication - Buket Kosova
EGE ÜNİVERSİTESİ, EGE TIP FAKÜLTESİ
1 shared publication - Cigdem Arikan
Department of Pediatric Gastroenterology, Hepatology and Nutrition, Koc University School of Medicine, Istanbul, Turkey
1 shared publication Duygu Tatlı
Bülent Ecevit University
1 shared publicationHacer Akturk
Koç University Pediatric infectious diseases Istanbul Turkey
1 shared publicationIbrahim Piskin
1 shared publication
Latest Publications
- 1 January 2026
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 20 (Supplement)
P0956Infliximab trough concentrations are associated with paediatric sonographic transmural healing targets in children with Inflammatory Bowel Disease
Background: Transmural healing (TH) is an emerging treatment target for IBD and is associated with superior outcomes compared to clinical or endoscopic healing. However, current paediatric proactive infliximab (IFX) therapeutic drug monitoring (pTDM) guidelines are based on clinical and biochemical outcomes. This study aimed to identify IFX trough concentration (cTrough) targets associated with TH assessed by intestinal ultrasound (IUS). Methods: This cohort study included paediatric IBD patients, <18 years of age, who started IFX and underwent IUS as part of routine clinical care. Patients with isolated upper GI disease, proctitis or no IUS follow-up were excluded. The primary outcome was the IFX induction cTrough associated with TH, defined as a maximum bowel wall thickness (BWT) <2.5mm per paediatric consensus and compared with the adult <3.0mm definition (+/- colour doppler signal). IUS was conducted following the International Bowel UltraSound (IBUS) acquisition consensus by two IBUS-certified paediatric gastroenterologists. IFX cTrough and antibodies (ATIs) were measured at the 3rd and 4th infusion and at maintenance intervals following pTDM guidelines. IFX and ATIs were measured by LC-MS/MS and ECLIA, respectively (Mayo Clinic Laboratories). Area under the receiver operating characteristics (AUROC) analyses were used to evaluate IFX cTrough cutoffs associated with TH. Results: The cohort included 66 children with IBD, 45 of whom met inclusion criteria (67 IFX cTrough-IUS pairs). Mean age 10 (IQR: 9-13) years of age, 53% (24) Crohn’s disease, and 58% (26) female. Patients with the paediatric TH target (BWT <2.5mm) had a higher median IFX induction cTroughs 39.5 μg/mL (24.5-50) compared to ≥ 2.5mm, 14 μg/mL (7.6-26.5; P=0.04). Patients with a maximum BWT <3.0 mm had higher IFX induction cTroughs 32 μg/mL (25-49) compared to ≥ 3.0mm, 14 μg/mL (7.6-23; P=0.03). At infusion-3, an IFX ≥22 μg/mL cutoff predicted TH (AUROC 0.74; sensitivity 0.80, specificity 0.80) for <2.5mm and (AUROC 0.78; sens 0.83, spec 0.89) for <3.0mm. At infusion-4, a cutoff of IFX ≥17 μg/mL (AUROC 0.75; sens 1.00, spec 0.71) predicted the paediatric TH target at < 2.5mm, while a cutoff of IFX ≥14 μg/mL (AUROC 0.82; sens 1.00, spec 0.75) predicted TH at the adult <3.0mm definition. Addition of colour doppler signal to BWT did not improve AUROC predictions. Moreover, maintenance IFX concentrations beyond infusion-4 did not predict TH. Conclusion: This study identified IFX cTroughs that predict paediatric transmural healing by intestinal ultrasound. Maintenance concentrations did not predict healing. Future intervention studies should evaluate if prospective optimized dosing results in enhanced transmural healing outcomes. Conflict of interest: Toroslu, Ertug: NOTHING TO DECLARE Patel, Perseus: None Colman, Ruben: No conflicts
- 1 January 2026
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 20 (Supplement)
P0956Infliximab trough concentrations are associated with paediatric sonographic transmural healing targets in children with Inflammatory Bowel Disease
Background: Transmural healing (TH) is an emerging treatment target for IBD and is associated with superior outcomes compared to clinical or endoscopic healing. However, current paediatric proactive infliximab (IFX) therapeutic drug monitoring (pTDM) guidelines are based on clinical and biochemical outcomes. This study aimed to identify IFX trough concentration (cTrough) targets associated with TH assessed by intestinal ultrasound (IUS). Methods: This cohort study included paediatric IBD patients, <18 years of age, who started IFX and underwent IUS as part of routine clinical care. Patients with isolated upper GI disease, proctitis or no IUS follow-up were excluded. The primary outcome was the IFX induction cTrough associated with TH, defined as a maximum bowel wall thickness (BWT) <2.5mm per paediatric consensus and compared with the adult <3.0mm definition (+/- colour doppler signal). IUS was conducted following the International Bowel UltraSound (IBUS) acquisition consensus by two IBUS-certified paediatric gastroenterologists. IFX cTrough and antibodies (ATIs) were measured at the 3rd and 4th infusion and at maintenance intervals following pTDM guidelines. IFX and ATIs were measured by LC-MS/MS and ECLIA, respectively (Mayo Clinic Laboratories). Area under the receiver operating characteristics (AUROC) analyses were used to evaluate IFX cTrough cutoffs associated with TH. Results: The cohort included 66 children with IBD, 45 of whom met inclusion criteria (67 IFX cTrough-IUS pairs). Mean age 10 (IQR: 9-13) years of age, 53% (24) Crohn’s disease, and 58% (26) female. Patients with the paediatric TH target (BWT <2.5mm) had a higher median IFX induction cTroughs 39.5 μg/mL (24.5-50) compared to ≥ 2.5mm, 14 μg/mL (7.6-26.5; P=0.04). Patients with a maximum BWT <3.0 mm had higher IFX induction cTroughs 32 μg/mL (25-49) compared to ≥ 3.0mm, 14 μg/mL (7.6-23; P=0.03). At infusion-3, an IFX ≥22 μg/mL cutoff predicted TH (AUROC 0.74; sensitivity 0.80, specificity 0.80) for <2.5mm and (AUROC 0.78; sens 0.83, spec 0.89) for <3.0mm. At infusion-4, a cutoff of IFX ≥17 μg/mL (AUROC 0.75; sens 1.00, spec 0.71) predicted the paediatric TH target at < 2.5mm, while a cutoff of IFX ≥14 μg/mL (AUROC 0.82; sens 1.00, spec 0.75) predicted TH at the adult <3.0mm definition. Addition of colour doppler signal to BWT did not improve AUROC predictions. Moreover, maintenance IFX concentrations beyond infusion-4 did not predict TH. Conclusion: This study identified IFX cTroughs that predict paediatric transmural healing by intestinal ultrasound. Maintenance concentrations did not predict healing. Future intervention studies should evaluate if prospective optimized dosing results in enhanced transmural healing outcomes. Conflict of interest: Toroslu, Ertug: NOTHING TO DECLARE Patel, Perseus: None Colman, Ruben: No conflicts
- 1 September 2021
- Published by Edizioni Minerva Medica in Gazzetta Medica Italiana Archivio per le Scienze Mediche
- Vol. 180 (6) , 274-279
Assessment of pediatric patients presenting to the pediatric emergency service due to electrical injury: a single center experience
Article: Assessment of pediatric patients presenting to the pediatric emergency service due to electrical injury: a single center experience - Gazzetta Medica Italiana - Archivio per le Scienze Mediche 2021 June;180(6):274-9 - Minerva Medica - Journals
- 1 September 2021
- Published by Edizioni Minerva Medica in Gazzetta Medica Italiana Archivio per le Scienze Mediche
- Vol. 180 (6) , 274-279
Assessment of pediatric patients presenting to the pediatric emergency service due to electrical injury: a single center experience
Article: Assessment of pediatric patients presenting to the pediatric emergency service due to electrical injury: a single center experience - Gazzetta Medica Italiana - Archivio per le Scienze Mediche 2021 June;180(6):274-9 - Minerva Medica - Journals
- Open Access
- 2 June 2021
- Published by Wiley in Pediatric Transplantation
- Vol. 25 (7) , e14061
A single‐center report of COVID‐19 disease course and management in liver transplanted pediatric patients
Background: In 2019, SARS‐CoV‐2 causing COVID‐19 emerged. Severe COVID‐19 symptoms may evolve by virtue of hyperactivation of the immune system. Equally, immunocompromised patients may be at increased risk to develop COVID‐19. However, treatment guidelines for children following liver transplantation are elusive.Methods: As a liver transplantation center, we diagnosed and followed up 10 children (male/female: 8/2) with a median age of 8.5 years (IQR: 5.2–11.0), with COVID‐19 post‐liver transplant between March 2019 and December 2020. COVID‐19 diagnosis was based on PCR test and or florid X‐ray findings compatible with COVID‐19 in the absence of other cause. We retrospectively collected clinical and laboratory data from electronic patient records following written consent from patients/parents.Results: Nine patients were diagnosed as definitive (PCR positive) with one patient being diagnosed as probable COVID‐19. Seven patients recovered without any support whereas three were admitted for non‐invasive oxygenation. Lymphopenia and/or high levels of serum IL‐6 were detected in four patients. Six patients mounted anti‐SARS‐CoV‐2 antibodies at median 30 days (IQR: 26.5–119.0) following COVID‐19 diagnosis. Antibiotic therapy, favipiravir, anakinra, and IVIG were used as treatment in 4,1,1 and 2 patients, respectively. Furthermore, we kept the tacrolimus with or without everolimus but stopped MMF in 2 patients. Importantly, liver allograft function was retained in all patients.Conclusions: We found that being immunocompromised did not affect disease severity nor survival. Stopping MMF yet continuing with tacrolimus was an apt treatment modality in these patients.
- 2 June 2021
- Published by Wiley in Pediatric Transplantation
- Vol. 25 (7) , e14061
Open AccessA single‐center report of COVID‐19 disease course and management in liver transplanted pediatric patients
Background: In 2019, SARS‐CoV‐2 causing COVID‐19 emerged. Severe COVID‐19 symptoms may evolve by virtue of hyperactivation of the immune system. Equally, immunocompromised patients may be at increased risk to develop COVID‐19. However, treatment guidelines for children following liver transplantation are elusive.Methods: As a liver transplantation center, we diagnosed and followed up 10 children (male/female: 8/2) with a median age of 8.5 years (IQR: 5.2–11.0), with COVID‐19 post‐liver transplant between March 2019 and December 2020. COVID‐19 diagnosis was based on PCR test and or florid X‐ray findings compatible with COVID‐19 in the absence of other cause. We retrospectively collected clinical and laboratory data from electronic patient records following written consent from patients/parents.Results: Nine patients were diagnosed as definitive (PCR positive) with one patient being diagnosed as probable COVID‐19. Seven patients recovered without any support whereas three were admitted for non‐invasive oxygenation. Lymphopenia and/or high levels of serum IL‐6 were detected in four patients. Six patients mounted anti‐SARS‐CoV‐2 antibodies at median 30 days (IQR: 26.5–119.0) following COVID‐19 diagnosis. Antibiotic therapy, favipiravir, anakinra, and IVIG were used as treatment in 4,1,1 and 2 patients, respectively. Furthermore, we kept the tacrolimus with or without everolimus but stopped MMF in 2 patients. Importantly, liver allograft function was retained in all patients.Conclusions: We found that being immunocompromised did not affect disease severity nor survival. Stopping MMF yet continuing with tacrolimus was an apt treatment modality in these patients.
- 1 June 2017
- Published by Edizioni Minerva Medica in Minerva Pediatrics
- Vol. 69 (4) , 370-372
Purpura Fulminans as the presenting manifestation in a patient with homozygous methylenetetrahydrofolate reductase gene mutation
Article: Purpura Fulminans as the presenting manifestation in a patient with homozygous methylenetetrahydrofolate reductase gene mutation - Minerva Pediatrica 2017 August;69(4):370-2 - Minerva Medica - Journals
- 1 June 2017
- Published by Edizioni Minerva Medica in Minerva Pediatrics
- Vol. 69 (4) , 370-372
Purpura Fulminans as the presenting manifestation in a patient with homozygous methylenetetrahydrofolate reductase gene mutation
Article: Purpura Fulminans as the presenting manifestation in a patient with homozygous methylenetetrahydrofolate reductase gene mutation - Minerva Pediatrica 2017 August;69(4):370-2 - Minerva Medica - Journals
- 29 August 2016
- Published by Caleo in Turkish Archives of Pediatrics
- Vol. 51 (3) , 162-165
A pediatric case of pituitary macroadenoma presenting with pituitary apoplexy and cranial nerve involvement: case report
Pituitary adenomas usually arise from the anterior lobe of the pituitary gland and are manifested with hormonal disorders or mass effect. Mass effect usually occurs in nonfunctional tumors. Pituitary adenomas may be manifested with visual field defects or rarely in the form of total oculomotor palsy. Visual field defect is most frequently in the form of bitemporal hemianopsia and superior temporal defect. Sudden loss of vision, papilledema and ophthalmoplegia may be observed. Pituitary apoplexy is defined as an acute clinical syndrome characterized with headache, vomiting, loss of vision, ophthalmoplegia and clouding of consciousness. The problem leading to pituitary apoplexy may be decreased blood supply in the adenoma and hemorrhage following this decrease or hemorrhage alone. In this article, we present a patient who presented with fever, vomiting and sudden loss of vision and limited outward gaze in the left eye following trauma and who was found to have pituitary macroadenoma causing compression of the optic chiasma and optic nerve on the left side on cranial and pituitary magnetic resonance imaging.
- 29 August 2016
- Published by Caleo in Turkish Archives of Pediatrics
- Vol. 51 (3) , 162-165
A pediatric case of pituitary macroadenoma presenting with pituitary apoplexy and cranial nerve involvement: case report
Pituitary adenomas usually arise from the anterior lobe of the pituitary gland and are manifested with hormonal disorders or mass effect. Mass effect usually occurs in nonfunctional tumors. Pituitary adenomas may be manifested with visual field defects or rarely in the form of total oculomotor palsy. Visual field defect is most frequently in the form of bitemporal hemianopsia and superior temporal defect. Sudden loss of vision, papilledema and ophthalmoplegia may be observed. Pituitary apoplexy is defined as an acute clinical syndrome characterized with headache, vomiting, loss of vision, ophthalmoplegia and clouding of consciousness. The problem leading to pituitary apoplexy may be decreased blood supply in the adenoma and hemorrhage following this decrease or hemorrhage alone. In this article, we present a patient who presented with fever, vomiting and sudden loss of vision and limited outward gaze in the left eye following trauma and who was found to have pituitary macroadenoma causing compression of the optic chiasma and optic nerve on the left side on cranial and pituitary magnetic resonance imaging.
- 28 December 2014
- Published by Springer Nature in Indian Journal of Pediatrics
- Vol. 82 (5) , 483-484
Late Presenting Congenital Diaphragmatic Hernia as Tension Gastrothorax
- 28 December 2014
- Published by Springer Nature in Indian Journal of Pediatrics
- Vol. 82 (5) , 483-484
Late Presenting Congenital Diaphragmatic Hernia as Tension Gastrothorax
- 1 January 2009
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 50 (6) , 912-917
Methylenetetrahydrofolate reductase C677T and A1298C gene polymorphisms and therapy-related toxicity in children treated for acute lymphoblastic leukemia and non-Hodgkin lymphoma
This study aimed to investigate the association of the methylenetetrahydrofolate reductase (MTHFR) gene C677T and A1298C polymorphisms with serum drug levels and toxicities after high-dose methotrexate (MTX) infusion. The study included 37 children with acute lymphoblastic leukemia or non-Hodgkin lymphoma. Serum MTX levels and toxicities of bone marrow, liver and kidney were analysed. Genotype analysis of the C677T and A1298C gene polymorphisms from genomic DNA of the subjects was performed by real-time PCR. Subjects with MTHFR polymorphism for C677T (CT, TT) had significantly higher MTX levels at 24 h (p = 0.009), and these genotypes did not seem to cause toxicity. Subjects with MTHFR polymorphism for A1298C (AC, CC) had significantly higher MTX levels at 48 h (p = 0.02), and had more grade III/IV anemia (p = 0.02), thrombocytopenia (p = 0.0001), elevated AST levels (p = 0.04) and frequent febrile neutropenic episodes (p = 0.004). The present study suggests that A1298C gene, but not C677T polymorphism is associated with MTX-related toxicity.
- 1 January 2009
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 50 (6) , 912-917
Methylenetetrahydrofolate reductase C677T and A1298C gene polymorphisms and therapy-related toxicity in children treated for acute lymphoblastic leukemia and non-Hodgkin lymphoma
This study aimed to investigate the association of the methylenetetrahydrofolate reductase (MTHFR) gene C677T and A1298C polymorphisms with serum drug levels and toxicities after high-dose methotrexate (MTX) infusion. The study included 37 children with acute lymphoblastic leukemia or non-Hodgkin lymphoma. Serum MTX levels and toxicities of bone marrow, liver and kidney were analysed. Genotype analysis of the C677T and A1298C gene polymorphisms from genomic DNA of the subjects was performed by real-time PCR. Subjects with MTHFR polymorphism for C677T (CT, TT) had significantly higher MTX levels at 24 h (p = 0.009), and these genotypes did not seem to cause toxicity. Subjects with MTHFR polymorphism for A1298C (AC, CC) had significantly higher MTX levels at 48 h (p = 0.02), and had more grade III/IV anemia (p = 0.02), thrombocytopenia (p = 0.0001), elevated AST levels (p = 0.04) and frequent febrile neutropenic episodes (p = 0.004). The present study suggests that A1298C gene, but not C677T polymorphism is associated with MTX-related toxicity.